TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18606919

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 988
Study: 15962392

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST) and endoscopic naso-bile drainage (ENBD)
Number of subjects: 90
Study: 11384090

Group type: EXPERIMENTAL
Intervention: 105AD7
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 9421109

Group type: EXPERIMENTAL
Intervention: Rifampin with ascorbic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin without ascorbic acid
Number of subjects: 0
Study: 8217599

Group type: EXPERIMENTAL
Intervention: 4‐HPR (N‐(4‐hydroxyphenyl) retinamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3305118

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 120 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28807738

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 1226
Study: 27385730

Group type: EXPERIMENTAL
Intervention: Experimental group (teachers trained to be more autonomy supportive and less controlling)
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Control group (teachers not receiving the intervention)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 1017
Study: 23072444

Group type: EXPERIMENTAL
Intervention: Working in construction
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Working in mining
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Working in agriculture
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Working in industry
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Working in trade
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Working in other services
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Working in transport
Number of subjects: 8316

Group type: EXPERIMENTAL
Intervention: Perception of neighbourhood security (third quartile of insecurity)
Number of subjects: 8316
Study: 21209232

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on the first day, then 75 mg once daily for 6 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sibutramine (15 mg oral dose)
Number of subjects: 13
Study: 19591674

Group type: EXPERIMENTAL
Intervention: Active PEMF-treatment for 60 days, four hours daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham-treatment for 60 days, four hours daily
Number of subjects: 68
Study: 16836628

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for depression
Number of subjects: 329

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 329
Study: 12638773

Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide tooth-whitening gel
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 10721386

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9262801

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Meperidine (2.0 mg/kg)/Promethazine (1.0 mg/kg)
Number of subjects: 10
Study: 8331703

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Sequential compression devices
Number of subjects: 395

Group type: COMPARATOR
Intervention: Low-dose heparin and Sequential compression devices
Number of subjects: 395

Group type: COMPARATOR
Intervention: Patients with spinal injuries
Number of subjects: 395

Group type: COMPARATOR
Intervention: Patients with severe head injuries
Number of subjects: 395
Study: 3581737

Group type: EXPERIMENTAL
Intervention: Cefoperazone (1 g)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Cefotaxime (1 g)
Number of subjects: 929
Study: 29551181

Group type: EXPERIMENTAL
Intervention: Single-use pre-filled flush syringes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Manually prepared syringes
Number of subjects: 48
Study: 27174549

Group type: EXPERIMENTAL
Intervention: Uniportal video‐assisted lobectomy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Other video‐assisted thoracoscopic lobectomy techniques
Number of subjects: 106
Study: 25549656

Group type: EXPERIMENTAL
Intervention: NMES robot group (n = 11)
Number of subjects: 26

Group type: COMPARATOR
Intervention: robot group (n = 15)
Number of subjects: 26
Study: 23043721

Group type: EXPERIMENTAL
Intervention: PRO+LEU (20 g casein protein + 2.5 g crystalline leucine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PRO (20 g casein protein)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PRO+LEU
Number of subjects: 24
Study: 19756888

Group type: EXPERIMENTAL
Intervention: MIS-TKR
Number of subjects: 100
Study: 18223530

Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone
Number of subjects: 30
Study: 22156381

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 4 mg i.v. every 6 months for 2 years
Number of subjects: 90

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg/day) without ZOL
Number of subjects: 90
Study: 15950351

Group type: EXPERIMENTAL
Intervention: Olanzapine in monotherapy (OGm)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Conventional antipsychotics (CG)
Number of subjects: 724
Study: 12558013

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9649102

Group type: EXPERIMENTAL
Intervention: Thermal uterine balloon therapy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Hysteroscopic rollerball ablation
Number of subjects: 255
Study: 7977519

Group type: EXPERIMENTAL
Intervention: Topical intravaginal clindamycin (dosages not specified, administered twice daily for 5 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3289300

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31600796

Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (UCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 0
Study: 29139142

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium (0.044 mg/kg, 0.132 mg/kg, 0.22 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium (10× the labeled starting dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium (up to 10× the labeled starting dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham-dose (0×)
Number of subjects: 32
Study: 28320484

Group type: EXPERIMENTAL
Intervention: Twice-daily intervention nutritional drink enriched with additional micronutrients, myo-inositol, and probiotics.
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Twice-daily control nutritional drink enriched with standard micronutrients.
Number of subjects: 1800
Study: 26214765

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 102
Study: 23863230

Group type: EXPERIMENTAL
Intervention: Early goal-directed sedation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard sedation
Number of subjects: 37
Study: 20620495

Group type: EXPERIMENTAL
Intervention: CsAm (Cyclosporine Minimization)
Number of subjects: 207

Group type: COMPARATOR
Intervention: CsAe (Cyclosporine Elimination)
Number of subjects: 207
Study: 18260770

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 0
Study: 17342882

Group type: EXPERIMENTAL
Intervention: Fluid intake at 8, 16, 24, and 32 kilometers (Early Trials)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Fluid intake at 10, 20, 30, and 40 kilometers (Late Trials)
Number of subjects: 7
Study: 14663127

Group type: EXPERIMENTAL
Intervention: Microscopists' readings of low grade NGU slides (5-20 p/hpf)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microscopists' readings of high grade NGU slides (>20 p/hpf)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microscopists' readings of negative slides (<5 p/hpf)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repeat readings by the same microscopist for negative slides
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repeat readings by the same microscopist for low grade slides
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repeat readings by the same microscopist for high grade slides
Number of subjects: 60
Study: 10962167

Group type: EXPERIMENTAL
Intervention: Artificial sweetener (10 parts cyclamate and 1 part saccharin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Glycine (sweet amino acid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 80
Study: 8869604

Group type: EXPERIMENTAL
Intervention: Partial inferior turbinectomy (PIT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cryosurgery (CS)
Number of subjects: 52
Study: 1500966

Group type: EXPERIMENTAL
Intervention: Composite resin restorative material (Heliomolar R.O.)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amalgam alloy restorations
Number of subjects: 104
Study: 6100488

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingually)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 28892807

Group type: EXPERIMENTAL
Intervention: Osteopathic Intervention (OI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: General Osteopathic Treatment (GOT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group (untreated)
Number of subjects: 50
Study: 27730033

Group type: EXPERIMENTAL
Intervention: 20 mg daily isotretinoin (Group A)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 20 mg alternate days isotretinoin (Group B)
Number of subjects: 240
Study: 24730718

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral affect
Number of subjects: 0
Study: 23853000

Group type: EXPERIMENTAL
Intervention: MenC-CRM glycoconjugate vaccine (CRM-group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No additional doses of MenC vaccine (control group)
Number of subjects: 124
Study: 20079691

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Control (no anthracycline treatment)
Number of subjects: 1762
Study: 19107254

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative stem cell transplantation (NST)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Myeloablative HSCT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both NST and myeloablative HSCT
Number of subjects: 34
Study: 17115520

Group type: EXPERIMENTAL
Intervention: Modelling group (expert- and self-modelling, performance feedback)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 16
Study: 15164106

Group type: EXPERIMENTAL
Intervention: 1.2 g/day nonesterified, nonhydrogenated plant sterols in low-fat milk (Lo)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 1.6 g/day nonesterified, nonhydrogenated plant sterols in low-fat milk (Hi)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0 g/day nonesterified, nonhydrogenated plant sterols in low-fat milk (C)
Number of subjects: 81
Study: 11495184

Group type: EXPERIMENTAL
Intervention: Coeducational prevention program for teenagers on sexual coercion, including communication skills training and enhanced instruction via video and interactive video 'virtual date'.
Number of subjects: 458

Group type: COMPARATOR
Intervention: Control condition (not specified).
Number of subjects: 458
Study: 9430755

Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Vasoconstrictor
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 202

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 202
Study: 8297301

Group type: EXPERIMENTAL
Intervention: Tapes
Number of subjects: 68

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 68

Group type: COMPARATOR
Intervention: Interrupted nylon sutures
Number of subjects: 68
Study: 15791754

Group type: EXPERIMENTAL
Intervention: CATI
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-CATI
Number of subjects: 0
Study: 31810389

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Lixisenatide (added to iGlar)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 1170
Study: 29444672

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 41
Study: 27130844

Group type: EXPERIMENTAL
Intervention: Baseline plasma concentrations of VEGF above cohort median
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Baseline plasma concentrations of sVEGFR1 above cohort median
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Membranous c‐Met protein levels
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Genomic DNA sequencing of cancer-related genes
Number of subjects: 503
Study: 24690184

Group type: EXPERIMENTAL
Intervention: Healthy Activity Program for moderate to severe depression plus enhanced usual care
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Counselling for Alcohol Problems for harmful and dependent drinking plus enhanced usual care
Number of subjects: 900

Group type: COMPARATOR
Intervention: Enhanced usual care only
Number of subjects: 900
Study: 23579892

Group type: EXPERIMENTAL
Intervention: GC Fuji II LC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caviton
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GC Fuji IX
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Kalzinol
Number of subjects: 80
Study: 20685303

Group type: EXPERIMENTAL
Intervention: Naturally occurring diterpenes such as forskolin and stevioside
Number of subjects: 0
Study: 18603398

Group type: EXPERIMENTAL
Intervention: Amoxicillin and ambroxol hydrochloride tablets
Number of subjects: 0
Study: 16619181

Group type: EXPERIMENTAL
Intervention: Towne/Toledo chimeric vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14971151

Group type: EXPERIMENTAL
Intervention: Combined therapy including adaptation to intermittent normobaric hypoxia and medicines
Number of subjects: 62

Group type: COMPARATOR
Intervention: Drugs alone (control group)
Number of subjects: 62
Study: 10406244

Group type: COMPARATOR
Intervention: H. pylori infection assessment using culture growth, histological tests, and CLOtest results.
Number of subjects: 2394
Study: 7588666

Group type: EXPERIMENTAL
Intervention: 6 microliters 0.25% bupivacaine + 0.05 mg kg‐1 midazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6 microliters 0.25% bupivacaine
Number of subjects: 30
Study: 2278060

Group type: EXPERIMENTAL
Intervention: Oral sulfadoxine-pyrimethamine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Intramuscular sulfadoxine-pyrimethamine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 186
Study: 396652

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/day, 25 mg in the morning and midday and 50 mg at bed time)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29203731

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy plus rescue therapy for ICAS
Number of subjects: 140

Group type: COMPARATOR
Intervention: Embolic group
Number of subjects: 140
Study: 27537997

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2238

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2238
Study: 24377485

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indwelling catheter-based multiple infiltrations of bupivacaine (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single dose of 0.5% bupivacaine infiltration (group C)
Number of subjects: 60
Study: 22274319

Group type: EXPERIMENTAL
Intervention: Brachytherapy with a total dose of 15Gy to point A followed by radical surgery (arm BT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy with cisplatin 50 mg/m plus 5‐fluorouracil 750 mg/m at a 2‐week interval for 2 courses followed by radical surgery (arm IVCT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with the same regimen as the IVCT arm followed by radical surgery (arm IACT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Radical surgery alone (arm RS)
Number of subjects: 123
Study: 20858029

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Camp as usual
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined groups (problem-solving intervention and camp as usual)
Number of subjects: 50
Study: 17690950

Group type: EXPERIMENTAL
Intervention: Taurine treatment (2 g taurine 3 times a day for three months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (without taurine for 4 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Taurine treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16858546

Group type: EXPERIMENTAL
Intervention: PHRSD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Roux-en-Y PPPD
Number of subjects: 32
Study: 12544522

Group type: EXPERIMENTAL
Intervention: Screening group (n = 10 townships)
Number of subjects: 4299

Group type: COMPARATOR
Intervention: Control group (n = 11 townships)
Number of subjects: 4299
Study: 10472562

Group type: EXPERIMENTAL
Intervention: Vincristine, Actinomycin D, Cyclophosphamide or Ifosfamide, Adriamycin (Doxorubicin), with or without Etoposide
Number of subjects: 631
Study: 8671497

Group type: EXPERIMENTAL
Intervention: Antibiotic-free medium
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Medium modified with half the standard antibiotic concentration
Number of subjects: 196

Group type: COMPARATOR
Intervention: Conventional medium (control group)
Number of subjects: 196
Study: 1917610

Group type: EXPERIMENTAL
Intervention: External beam irradiation
Number of subjects: 104
Study: 6162389

Group type: EXPERIMENTAL
Intervention: Topical application of compound 48/80
Number of subjects: 25

Group type: COMPARATOR
Intervention: Histamine H1 receptor antagonist, antazoline phosphate
Number of subjects: 25
Study: 6140441

Group type: EXPERIMENTAL
Intervention: Component vaccine containing purified haemagglutinins (HAs) of Bordetella pertussis
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Conventional whole-cell vaccine
Number of subjects: 5000
Study: 30903525

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (1064 nm) applied at 3000 J with 20 J/cm2 for 15 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control side (no intervention)
Number of subjects: 30
Study: 29626849

Group type: EXPERIMENTAL
Intervention: Nalbuphine at the ED95 dose (0.128 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil at an equivalent dose
Number of subjects: 60
Study: 29939698

Group type: EXPERIMENTAL
Intervention: Preprocedural flurbiprofen axetil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oxybuprocaine jelly alone
Number of subjects: 52
Study: 23887713

Group type: EXPERIMENTAL
Intervention: Phospho-histone H3 (pHH3) expression
Number of subjects: 339

Group type: COMPARATOR
Intervention: Ki-67 expression
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: pHH3 expression
Number of subjects: 339
Study: 22468945

Group type: EXPERIMENTAL
Intervention: Concord grape juice for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 0
Study: 20886801

Group type: EXPERIMENTAL
Intervention: Medicated thread moxibustion of traditional Zhuang nationality medicine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Simple plum-blossom needle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle combined with medicated thread moxibustion
Number of subjects: 150
Study: 17875030

Group type: EXPERIMENTAL
Intervention: Supported Group Residence (SGR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient group (Control)
Number of subjects: 0
Study: 16163530

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Balanced (placebo) amino acid mixture
Number of subjects: 42
Study: 11882622

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d) for up to 5 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no ACEi treatment), n=7
Number of subjects: 7
Study: 10431866

Group type: EXPERIMENTAL
Intervention: Washed postoperative drainage fluid (Group A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 112
Study: 7581139

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron infusion for 3 days during CY administration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron infusion for 7 days during Bu/CY administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: MCP plus droperidol
Number of subjects: 60
Study: 2213777

Group type: EXPERIMENTAL
Intervention: Numerical Rating Scale (NRS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Verbal Rating Scale (VRS)
Number of subjects: 91
Study: 121048

Group type: EXPERIMENTAL
Intervention: 1 mg oestriol + 2 mg oestradiol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 8 mg oestriol succinate + 1 mg oestradiol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: oestriol succinate
Number of subjects: 4

Group type: COMPARATOR
Intervention: 2 mg oestradiol
Number of subjects: 4

Group type: COMPARATOR
Intervention: 1 mg oestradiol
Number of subjects: 4
Study: 31864960

Group type: EXPERIMENTAL
Intervention: Infant-directed (ID) speech
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adult-directed (AD) speech
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bicycle ringtones and ID speech
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Categorical mismatch (human speech to furniture target images)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bicycle ringtones
Number of subjects: 37